Drugs / Tetraethylammonium
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00185003 | Jan 2003 → Jun 2005 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00166166 | Jul 2002 → Jan 2013 | hyperlipidemia | Emory University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetraethylammonium | “Intrabrachial infusion of the K-channel blocker tetraethylammonium (TEA) completely restored the vasoconstrictor response to norepinephrine” PMID 16864730 ↗ Jul 2006 |
| Known as | TEA | “Intrabrachial infusion of the K-channel blocker tetraethylammonium (TEA) completely restored the vasoconstrictor response to norepinephrine” PMID 16864730 ↗ Jul 2006 |
| Action | Inhibit | “Tetraethylammonium chloride (TEA) was used to inhibit K(+)(Ca) channel activation” PMID 21555712 ↗ May 2011 |
| Route | Other | “Intrabrachial infusion of the K-channel blocker tetraethylammonium (TEA)” PMID 16864730 ↗ Jul 2006 |